Ventrus shares soar on PhIII pain data; Maxygen earns $30M payment from Bayer; Big Pharma backs university collab;

 @FierceBiotech: FDA panel gave Gilead's key HIV drug Quad the OK on Friday. More | Follow @FierceBiotech

 @RyanMFierce: Category: Things CROs are good at. Wrong answer: Patient recruitment for clinical trials. Article | Follow @RyanMFierce

 @JohnCFierce: Come back from vacation to find lorcaserin looking pretty good for an approval. But how much could Arena really make from it? | Follow @JohnCFierce

> Shares of Ventrus Biosciences ($VTUS) shot up 19% this morning after the developer announced positive results from a late-stage study of its experimental medication VEN 307, which is being developed to treat pain associated with anal fissures. Story

> San Mateo, CA-based Maxygen ($MAXY) has earned a final, $30 million contingency payment from Bayer for a hemophilia treatment. Bayer initially paid $90 million upfront in 2008 for rights to the therapy. Release

> Fierce 15 winner F-star, an antibody developer, has undergone a management makeover. The biotech says it named Dr. John Haurum as the new CEO and will concentrate all of its R&D work in Cambridge in the U.K. Release

> Six top pharma companies, including Pfizer ($PFE), Merck Serono and GlaxoSmithKline ($GSK), have committed £14.4 million in support for a long-term collaboration between academic investors and pharma scientists. Report

> In the wake of a positive expert panel vote, Eisai has expanded its marketing deal with Arena on the obesity drug lorcaserin. Story

Pharma News

 @FiercePharma: Merck Serono workers threaten to strike in opposition to Geneva HQ closure. Already, protestors have hit the streets. | Follow @FiercePharma

> Eisai broadens marketing deal for Arena's weight-loss drug. Story

> Sales-needy Takeda springs for emerging markets growth. Article

> Servier, founder face trial on Mediator charges. News

Medical Devices News

 @FierceMedDev: Medtronic's latest study attempts to convince you that CRT-Ds are a bargain. More | Follow @FierceMedDev

> Regentis grabs $10M Series C for cartilage regeneration implant trials. Article

> FDA panel wants higher standard for obesity-treating devices. Story

> D. Medical eyes world stage for insulin infusion device. More

> Consumer group wary of industry concessions in FDA user fee bill. Report

Biotech IT News

> Join a live Twitter chat with Medidata's Glen de Vries. More

> BioClinica chief touts Microsoft ties in Q1 report. News

> Boehringer, pharmas turn to social gaming for online outreach. Article

> Roche unit allies with genomics software group SoftGenetics. More

> NIH pumps $6M into DNA analysis for Alzheimer's plan. Item

And Finally… Sir Chris Evans has outlined some ambitious plans for Wales' new biotech venture fund. Companies can gain up to $16 million, says Evans. Story


Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.